Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Income (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Operating Income for 6 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 898.99% year-over-year to $16.8 million, compared with a TTM value of $24.9 million through Dec 2025, up 173.99%, and an annual FY2025 reading of $24.9 million, up 173.99% over the prior year.
  • Operating Income was $16.8 million for Q4 2025 at Xeris Biopharma Holdings, up from $6.7 million in the prior quarter.
  • Across five years, Operating Income topped out at $16.8 million in Q4 2025 and bottomed at -$48.3 million in Q4 2021.
  • Average Operating Income over 5 years is -$12.5 million, with a median of -$13.8 million recorded in 2023.
  • The sharpest move saw Operating Income crashed 162.43% in 2024, then skyrocketed 898.99% in 2025.
  • Year by year, Operating Income stood at -$48.3 million in 2021, then soared by 68.57% to -$15.2 million in 2022, then skyrocketed by 35.13% to -$9.8 million in 2023, then soared by 117.06% to $1.7 million in 2024, then surged by 898.99% to $16.8 million in 2025.
  • Business Quant data shows Operating Income for XERS at $16.8 million in Q4 2025, $6.7 million in Q3 2025, and $4.5 million in Q2 2025.